2-methoxyestradiol (2ME2) is a potent antiangiogenic molecule that inhibits the expression of hypoxia-inducible factor (HIF)-1α and, consequently, of VEGF and other HIF-1α target genes.

Our earlier studies demonstrated that human NF1 tumour cell lines either went through apoptosis or ceased growth in the presence of 2-methoxyoestradiol (2ME2), a naturally occurring anticancer ...

This is an ASCO Meeting Abstract from the 2008 ASCO Annual Meeting. This abstract does not include a full text component.

2-methoxyestradiol (meth-oxy-es-tra-di-ol), or 2ME2, (trade name Panzem), is currently in clinical trials by other researchers as a treatment for various cancers. Mayo Clinic recently completed a ...

by the U.S. Patent & Trademark Office and contains composition and method claims covering the combination of 2ME2 and methotrexate for the treatment of rheumatic diseases, including rheumatoid ...

Researchers announced on Wednesday that it would be safe to extend human trials on Folkman's cancer-fighting drug, called 2ME2 (2-methoxyestradiol). The drug, which can be taken as a pill ...

The study, which was done in mouse models, is featured on the cover of the November issue of Cancer Research. 2-methoxyestradiol (meth-oxy-es-tra-di-ol), or 2ME2, (trade name Panzem), is currently in ...

Iwaniec and Turner studied the effect of 2-methoxyestradiol (meth-oxy-es-tra-di-ol), or 2ME2, on the bone. 2ME2 is derived from estrogen and works by suppressing tumor growth and blocking the ...